Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 3 Summary of the best radiologic response (modified response evaluation criteria in solid tumors) following transarterial radioembolization

	All procedures (n = 169)	TARE_alone (n = 63)	TARE_sorafenib (n = 81)	TARE_no_sorafenib (n = 25)
Treated area
CR	12 (7.1)	2 (3.2)	9 (11.1)	1 (4)
PR	61 (36.1)	24 (38.1)	34 (42)	3 (12)
SD	66 (39.1)	28 (44.4)	28 (34.6)	10 (40)
PD	30 (17.8)	9 (14.3)	10 (12.3)	11 (44)
OR	73 (43.2)	26 (41.3)	43 (53.1)	4 (16)
DC	139 (82.2)	54 (85.7)	71 (87.7)	14 (56)
Intrahepatic area
CR	12 (7.1)	2 (3.2)	9 (11.1)	1 (4)
PR	58 (34.3)	22 (34.9)	33 (40.7)	3 (12)
SD	59 (34.9)	26 (41.3)	26 (32.1)	7 (28)
PD	40 (23.7)	13 (20.6)	13 (16)	14 (56)
OR	70 (41.4)	24 (38.1)	42 (51.9)	4 (16)
DC	129 (76.3)	50 (79.4)	68 (84)	11 (44)
Overall
CR	10 (5.9)	2 (3.2)	7 (8.6)	1 (4)
PR	52 (30.8)	22 (34.9)	28 (34.6)	2 (8)
SD	56 (33.1)	26 (41.3)	23 (28.4)	7 (28)
PD	51 (30.2)	13 (20.6)	23 (28.4)	15 (60)
OR	62 (36.7)	24 (38.1)	35 (43.2)	3 (12)
DC	107 (69.8)	50 (79.4)	58 (71.6)	10 (40)

Values represent number of procedures (%). Objective response consisted of complete response (CR) and partial response (PR). Disease control consisted of CR, PR and stable disease. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; OR: Objective response; DC: Disease control; TARE: Transarterial radioembolization.